Exsilio Therapeutics develops genomic medicines designed to permanently insert therapeutic genes via RNA intermediate templates and deliver them in lipid nanoparticles. Its technology is based on naturally occurring genetic elements engineered through predictive in silico modeling and wet lab experimentation for precise insertion into safe-harbor sites of disease-relevant cells. The company aims to treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions, by encoding genes that integrate permanently rather than producing transient effects. Exsilio plans to use its platform to insert whole genes with a repeatable and titratable approach, potentially addressing patients irrespective of individual mutations. Led by CEO Tal Zaks, the company intends to advance lead candidates toward development and expand operations using the new financing. The article does not disclose revenue or user metrics.

Total raised

$82M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2024